Press Release

Proteomics Market to Grow with a CAGR of 12.21% through 2028

Rising demand for personalized medicine and increasing R&D expenditure & government funding for proteomics is expected to drive the Global Proteomics Market growth in the forecast period, 2024-2028.


According to TechSci Research report, “Proteomics Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2028”, the Global Proteomics Market stood at USD 35.88 billion in 2022 and is anticipated to grow with a CAGR of 12.21% in the forecast period, 2024-2028. The remarkable growth of the Global Proteomics Market can be primarily attributed to the surge in research activities focused on personalized medicine.

With the increasing investments in research and development by pharmaceutical and biotechnology companies, coupled with continuous technological advancements, the field of proteomics is experiencing a significant boost. Moreover, the rising amount of monetary support provided by governments worldwide further fuels the expansion of this market, fostering innovation and driving breakthrough discoveries in the field.


Browse over XX market data Figures spread through XX Pages and an in-depth TOC on " Proteomics Market.”


The proteomics industry is poised for significant growth and advancements in the near future. Proteomics, the study of proteins and their functions within biological systems, plays a crucial role in understanding disease mechanisms, identifying therapeutic targets, and developing personalized medicine approaches. With advancements in technology and analytical techniques, the proteomics industry is expected to witness remarkable progress. One of the key areas of growth is the development of high-throughput proteomics platforms that enable the analysis of large numbers of proteins simultaneously. This allows for a comprehensive understanding of complex protein networks and their interactions, leading to insights into disease pathways and potential biomarkers. Additionally, advancements in mass spectrometry and bioinformatics tools are enhancing the accuracy and speed of protein identification and quantification. This enables researchers to delve deeper into proteomic data and extract meaningful information for drug discovery, precision medicine, and diagnostics. Moreover, the integration of proteomics with other omics technologies, such as genomics and metabolomics, holds immense potential for gaining a holistic understanding of biological systems and disease processes. Overall, the proteomics industry is expected to contribute significantly to advancements in medical research, diagnostics, and therapeutic development, ultimately leading to improved patient outcomes soon.

Another growth driver of the Global Proteomics Market is the increasing prevalence of cancer and other diseases. Ongoing proteomics research can aid doctors in understanding how proteins react in dynamic environments, such as in patients with cancer. The field of proteomics can provide significant information in the form of biomarkers. However, there are also significant challenges to the growth of the Global Proteomics Market. Venturing into proteomics requires substantial capital expenditure on equipment and carries the risk of failure due to the trial-and-error nature of research.

Despite these challenges, the proteomics market presents several growth opportunities as a relatively new technology that has shown considerable progress. Nanoproteomics, which combines nanotechnology with proteomics, is expected to have a positive impact on market growth in the forecast period.

Increased investments by leading players in the development of improved medications and diagnostic technologies are expected to promote expansion in the proteomics market. For example, in June 2021, Bruker Corp. plans to release two new Tim stop equipment. These advancements enable the development of innovative methods and applications, such as epiproteomics/PTM characterization and the discovery of unbiased and comprehensive multi-omic biomarkers. They also improve and facilitate unique applications and methodologies in cancer liquid biopsy research. Such corporate activities are likely to augment market expansion in the coming years.

These key drivers will continue to propel the biopharmaceutical industry's pursuit of breakthrough pharmaceuticals, along with recent technology improvements in gene and protein research. In December 2020, Thermo Fisher Scientific announced the successful conclusion of its purchase of Phitonex, Inc., a North Carolina-based company that has developed a spectroscopic dye platform for elevated biology applications, accelerating research and development in immuno-oncology, cell therapy, and immunology research. The addition of Phitonex's products will allow Thermo company to offer more flow cytometry and image multiplexing capabilities to meet evolving client needs in protein and cell analysis investigations. As it is challenging for corporations to possess all the necessary knowledge to cover all tasks involved in proteomics, alliances are becoming increasingly essential in this market.

Furthermore, the increased prevalence of chronic diseases such as cancer, cardiovascular disorders (CVDs), respiratory diseases, chronic kidney disease (CKD), and others is expected to propel market expansion. As the prevalence of life-threatening diseases rises, the need for tailored therapeutics increases, resulting in a beneficial impact on the sector.


The Global Proteomics Market is segmented into product, technology, application, type, end user, regional distribution, and company.

Based on application, the clinical diagnostics segment is projected to hold the largest market share in the upcoming years, having already dominated the market in 2022. The increased utilization of proteomics for disease identification will drive market growth in the future. Early detection of diseases not only mitigates the risk of mortality but also aids in understanding potential biomarkers and risk factors. Consequently, this technique presents a significant growth opportunity. Furthermore, proteomics facilitates the identification and classification of tumors.

In addition, the drug discovery segment is anticipated to exhibit substantial growth, with the fastest compound annual growth rate in the years to come. The development of structure-based drug design will contribute significantly to market expansion. The rising demand for personalized drugs has played a pivotal role in driving market growth, leading to increased investments in this field. Early disease detection also fuels the necessity for drug development. The incorporation of proteomics technology enhances the drug discovery process, resulting in significant time savings for pharmaceutical companies. Moreover, the implementation of this technology has the potential to reduce capital expenditures associated with drug discovery. Ultimately, both the healthcare system and patients stand to benefit from the advancements offered by this technology.


Based on region, North America segment is expected to grow during the forecast period. Antibody-drug conjugates and protein therapies play a crucial role in the treatment and diagnosis of diseases in North America. This field is continuously expanding, with extensive research focused on innovative and next-generation medicines. Numerous protein therapies are currently undergoing clinical trials to address cancer, immunological disorders, infections, age-related diseases, and various other conditions. Moreover, proteomics research is thriving, particularly in countries like the United States. The prevalence of hereditary disorders such as cancer, as well as infectious diseases like malaria and tuberculosis, is driving the demand for proteomic services in the region.

Europe is expected to be the second-largest market for proteomics. The growth of the market in this region is fueled by increasing cancer research activities and government support. The Asia-Pacific region is projected to be the fastest-growing market due to the rising prevalence of cancer and other diseases, as well as the presence of numerous personalized medicine producers. In addition, the huge population, increasing incidence of cancer and infectious diseases, and widespread use of proteomics in genetic disorder diagnostics position East Asia and South Asia for significant expansion in the global market throughout the forecast period. Rising research and development expenditures and social programs are projected to drive substantial growth in the diagnosis of diseases based on proteomic approaches in these regions.


Major companies operating in Global Proteomics Market are:

  • Illumina, Inc.
  • Thermo Fisher Scientific Company Profile
  • Bruker Corporation
  • Promega Corporation
  • Agilent Technologies Inc. Company Profile
  • Merck KGaA.
  • Bio-Rad Laboratories, Inc. Company Profile
  • Danaher Corporation Company Profile
  • F Hoffmann-La Roche Ltd.
  • Luminex Corporation


Download Free Sample Report

Customers can also request for 10% free customization on this report.


“The growing preference for personalized drugs, coupled with the increasing focus on research and development in drug discovery and biotechnology, serves as the primary driver for market growth. Proteomic systems play a pivotal role in reducing the time, cost, and resources required for chemical synthesis and biological testing of drugs, thereby simplifying the drug discovery process. Moreover, the market is further propelled by opportunities associated with biomarker identification and mass spectrometry-based proteomics. Additionally, the market benefits from the rising technological penetration in comprehensive protein analysis techniques, enabling comprehensive quantitative and qualitative analysis of proteins, as well as identification of cancer therapies and treatments. Furthermore, favorable government policies supporting extensive research and development (R&D) efforts contribute to the market's growth.,” said Mr. Karan Chechi, Research Director with TechSci Research, a research-based management consulting firm.

Proteomics Market Segmented By Product (Reagents & Assays, Instruments, Software & Services), By Technology (Spectroscopy, Microarray instruments, Chromatography, X-ray crystallography, Protein Microarrays, Electrophoresis), By Application (Clinical Diagnostic, Drug Discovery, Diagnostic Biomarker Discovery, Others), By Type (Expression, Functional, Structural, Computational), By End User (Pharmaceutical and Biotechnology Companies, Research Institutes, CROs), By Region and Competition, Forecast & Opportunities, 2018-2028F”, has evaluated the future growth potential of Global Proteomics Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Proteomics Market.


Mr. Ken Mathews         

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656                                                     

Email: [email protected]               


Relevant News